Bottom line
FPHAX vs PRHSX: the short answer
FPHAX (Pharmaceuticals Portfolio) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) are quite different portfolios: only about 37% of their top holdings (by weight) are shared.
But PRHSX is far broader, holding 279 positions to 57 for FPHAX, so beyond the top names it adds exposure FPHAX doesn't have.
FPHAX is cheaper at 0.67% vs 0.83% — a difference of $16 a year per $10,000 invested.
Over five years, FPHAX returned +12.6% a year vs +4.2% for PRHSX (reporting dates differ).
Updated Nov 19, 2026
FPHAX vs PRHSX side by side
| FPHAX | PRHSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Fidelity | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.67% | 0.83% |
| Annual cost per $10k | $67 | $83 |
| 10-yr cost on $10k (prospectus) | $835 | $1,025 |
| Max front load | — | — |
| 12b-1 fee | 0% | — |
| 1-yr return | +30.3% | +17.7% |
| 5-yr return (annualized) | +12.6% | +4.2% |
| 10-yr return (annualized) | +10.0% | +9.1% |
| Best quarter | +18.5% | +23.5% |
| Worst quarter | −13.6% | −15.8% |
| Net assets (fund) | $1.5B | $11.9B |
| Number of holdings | 57 | 279 |
| Portfolio turnover | 77% | 62% |
| Returns as of | Apr 30, 2026 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FPHAX | PRHSX | Difference |
|---|---|---|---|
| 2025 | +30.3% | +17.7% | +12.6% |
| 2024 | +9.4% | +1.8% | +7.6% |
| 2023 | +12.5% | +3.1% | +9.4% |
| 2022 | +1.0% | −12.2% | +13.2% |
| 2021 | +11.8% | +13.3% | −1.5% |
| 2020 | +11.1% | +30.1% | −19.1% |
| 2019 | +31.6% | +29.1% | +2.5% |
| 2018 | +5.8% | +1.2% | +4.6% |
| 2017 | +10.7% | +28.0% | −17.3% |
| 2016 | −16.3% | −10.4% | −5.9% |
Source: Fund prospectus bar charts
Holdings overlap
5 of FPHAX's top 25 holdings also appear in PRHSX's top 25.
| Holding | FPHAX | PRHSX |
|---|---|---|
| ELI LILLY and CO | 28.78% | 14.28% |
| MERCK and CO INC | 4.74% | 4.01% |
| Gilead Sciences Inc | 3.97% | 2.82% |
| JOHNSON and JOHNSON | 3.77% | 6.63% |
| Moderna Inc | 1.57% | 0.83% |
Source: SEC Form N-PORT
FPHAX top 10
- ELI LILLY and CO — 28.78%
- Gsk Plc — 8.17%
- Viatris Inc — 5.45%
- Ucb Sa — 5.09%
- MERCK and CO INC — 4.74%
- Roche Holding Ag — 4.54%
- Legend Biotech Corp — 4.53%
- Astrazeneca Plc — 4.22%
- Elanco Animal Health Inc — 4.15%
- Jazz Pharmaceuticals Plc — 4.09%
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
FAQ
What is the difference between FPHAX and PRHSX?
Which is cheaper, FPHAX or PRHSX?
Should I own both FPHAX and PRHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.